CD30

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019

Retrieved on: 
Giovedì, Aprile 4, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Monoclonal antibodies, Cancer treatments, Seattle Genetics, Clinical medicine, Drugs, Antibody-drug conjugates, CD30, Brentuximab vedotin, Monomethyl auristatin E, Enfortumab vedotin, Glembatumumab vedotin

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets.
  • Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
  • ADCETRIS(brentuximab vedotin) utilizes the companys industry-leading ADC technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.
  • Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.

Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin

Retrieved on: 
Giovedì, Marzo 28, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Clinical medicine, Cancer treatments, Medicine, Monoclonal antibodies, Seattle Genetics, Antibody-drug conjugates, Immunology, Antineoplastic drugs, Brentuximab vedotin, CD30, Enfortumab vedotin, Monomethyl auristatin E

Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced in a press release earlier today.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced in a press release earlier today.
  • ADCETRIS(brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.
  • Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.
  • Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer.

Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference

Retrieved on: 
Martedì, Marzo 5, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Cancer treatments, Clinical medicine, Monoclonal antibodies, Seattle Genetics, Medicine, Takeda Pharmaceutical Company, Antibody-drug conjugates, Brentuximab vedotin, Immunology, CD30, Monomethyl auristatin E

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m. Eastern Time.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m. Eastern Time.
  • The presentation will be webcast live and available for replay from Seattle Genetics website at www.seattlegenetics.com in the Investors section.
  • Seattle Genetics, Inc.is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives.
  • ADCETRIS(brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.

Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day

Retrieved on: 
Mercoledì, Febbraio 6, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Cancer treatments, Monoclonal antibodies, Clinical medicine, Seattle Genetics, Medicine, Antibody-drug conjugates, Brentuximab vedotin, Immunology, Monomethyl auristatin E, CD30

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time.
  • The presentation will be webcast live and available for replay from Seattle Genetics website at www.seattlegenetics.com in the Investors section.
  • Seattle Genetics, Inc.is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives.
  • ADCETRIS(brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

Retrieved on: 
Martedì, Gennaio 22, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Cancer treatments, Monoclonal antibodies, Clinical medicine, Medicine, Seattle Genetics, Antibody-drug conjugates, Immunology, Brentuximab vedotin, Monomethyl auristatin E, Enfortumab vedotin, CD30, Glembatumumab vedotin

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets.
  • Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
  • ADCETRIS(brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.
  • Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

Retrieved on: 
Venerdì, Novembre 16, 2018
Medicine, Cancer, Clinical medicine, Monoclonal antibodies, Lymphoma, CD30, Brentuximab vedotin, Anaplastic large-cell lymphoma, Chemotherapy, Food and Drug Administration, Seattle Genetics, Millennium Pharmaceuticals

This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.

Key Points: 
  • This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.
  • "When the sponsor submits the completed application, the review team will already be familiar with the data and be able to conduct a more efficient, timely and thorough review.
  • RTOR allowed the FDA to approve this indication within two weeks of the completed application's submission."
  • Adcetris is now approved to treat previously untreated systemic anaplastic large cell lymphoma (ALCL) and other CD30-expressing PTCLs in combination with chemotherapy.